General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-16 | 2024-03 | -0.14 | -0.14 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.14 | N/A | N/A |
2023-12-22 | 2023-09 | -0.16 | -0.16 | N/A | N/A |
2023-08-11 | 2023-06 | -0.17 | -0.19 | -0.02 | -11.76% |
2023-05-12 | 2023-03 | 0 | -0.19 | N/A | N/A |
2023-02-14 | 2022-12 | 0 | -0.18 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-11 | EF Hutton | Upgrade | Buy | Buy |
2023-03-08 | EF Hutton | Upgrade | Buy | |
2022-12-28 | EF Hutton | Upgrade | Buy | |
2022-04-06 | EF Hutton | Upgrade | Buy | |
2020-01-12 | HC Wainwright & Co. | Upgrade | Buy | |
2013-02-19 | Taglich Brothers | Upgrade | Speculative Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-07-05 | BAILLAVOINE BRUNO JEAN-MARIE | Director | 5.97K | Purchase |
2021-04-21 | CIPRIANO JOHN S | Officer | 63.11K | Sale |
2016-08-30 | DE CLARA MAXIMILIAN D | Former | 675.12K | Stock Award(Grant) |
2024-05-07 | KERSTEN GEERT R | Chief Executive Officer | 1.20M | Purchase |
2010-03-17 | KINSOLVING C RICHARD | Director | 302.25K | Sale |
2024-05-07 | PRICHEP PATRICIA B | Officer | 232.33K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.90M | 4.58M | 4.02% |
2023-06-29 | Blackrock Inc. | 753.70K | 1.82M | 1.59% |
2023-06-29 | D.A. Davidson & Co. | 529.19K | 1.28M | 1.12% |
2023-06-29 | Geode Capital Management, LLC | 423.50K | 1.02M | 0.90% |
2023-06-29 | Osaic Holdings Inc | 386.02K | 930.30K | 0.82% |
2023-06-29 | Susquehanna International Group, LLP | 180.09K | 434.02K | 0.38% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 2.97M | 2.61% |
2023-06-29 | Vanguard Extended Market Index Fund | 591.63K | 1.43M | 1.25% |
2023-05-30 | Fidelity Extended Market Index Fund | 209.39K | 502.53K | 0.44% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 83.60K | 201.48K | 0.18% |
2023-08-30 | iShares Micro Cap ETF | 80.75K | 112.24K | 0.17% |
2023-05-30 | Fidelity Total Market Index Fund | 62.12K | 149.10K | 0.13% |
Dividend | Date |
---|---|
0.25 | 1996-08-28 |
Split | Date |
---|---|
1 : 25 | 2017-06-15 |
0.1 : 1 | 2013-09-25 |
1 : 10 | 1995-05-01 |
Nothing really has changed. Original PIII data had more than enough efficacy given zero toxicity and orphan drug. COVID unmasked corrupt nature of FDA. This is about protecting the franchise of Keytruda. Delays have further lined pockets of big pharma. I still think Geert may be part of this scenario. MK should have been approved months ago.
. Consequently, in order to stimulate product development and innovation, Congress in 1984 enacted Title II of the Drug Price Competition and Patent Term Restoration Act (Public Law 98-417) to extend patent life to compensate patent holders for marketing time lost while developing the product and awaiting government approval. Title II of the Act created a program whereby patent holders whose patents claim a human drug product, medical device, food additive or color additive could recoup some of the lost patent time.
MK would be classified as an orphan drug.
It treats a condition with no real new types of therapy in decades and - importantly - has ZERO toxicity. There is already enough data for approval for such a drug.. Companies like Merck most likely have franchise drugs that Keytruda in H&N cancer trials. The FDA is being bought off to protect such franchise drugs. My question is has Geert been bought off as well. As soon as CVM is bled dry and sold to a big pharma company for $20/s, MK will amazingly get fast track approval. That’s a far cry from the $150-$200/sh a stand alone CVM would bring with approval.
MK would be classified as an orphan drug.
It treats a condition with no real new types of therapy in decades and - importantly - has ZERO toxicity. There is already enough data for approval for such a drug.. Companies like Merck most likely have franchise drugs that Keytruda in H&N cancer trials. The FDA is being bought off to protect such franchise drugs. My question is has Geert been bought off as well. As soon as CVM is bled dry and sold to a big pharma company for $20/s, MK will amazingly get fast track approval. That’s a far cry from the $150-$200/sh a stand alone CVM would bring with approval.
A vaccine that kills children gets approved but a drug that saves lives gets ignored. I keep telling you people the FDA is not about saving lives
https://www.igor-chudov.com?utm_source=navbar&utm_medium=web
If the FDA was about saving lives, they would never have demonized ivermectin nor would they still be pushing the COVID vaccine. MK will not be approved until it is submitted by BIG pharma. - not bc of the lives it will save - but bc of the money it will make.
Who posted the Trump disinformation? Trump only asked there be an investigation - esp in light of the early morning ballot dumps after the ‘water main’ break. We have enough headaches with Geert. Let’s focus on that. Go to an MSNBC board if you want to hate on Trump and ignore the Biden crime family.
The same FDA that approves a dangerous COVID vaccine for children will not approve a lifesaving NON TOXIC treatment for adults with cancer. People need to understand this is more about politics, payoffs and agendas rather than medicine and healing. No vaccine with the side effects documented with the COVID vaccine would have ever gotten such widespread regulatory approval in the past. I have been following MK since 1990. It should have received some type of limited approval long ago.
How many of you know that both Opdivo and Keytruda are both approved for head and neck cancer patients that fail Conventional chemotherapy? The FDA has exhibited how corrupt they are by suppressing the use of effective treatments, like ivermectin and promoting a flawed, clearly dangerous Covid vax. Don’t think this corruption doesn’t extend to other therapeutics as well. Big Pharma will do whatever it takes to protect their franchise drugs. Nothing else explains why a non-toxic therapy for a fatal disease with proven efficacy has taken so long to get approval.